Want to see JP:7649 full AI Analyst Report?
Top Page
Sugi Holdings Co
(7649)
Select Model
Select Model
Rating:67Neutral
Price Target:
¥3,170.00
▲(8.93% Upside)
Action:Reiterated
Date:07/11/26
The score is primarily supported by solid financial performance—strong revenue growth and a notable 2026 cash flow rebound—partly offset by rising leverage since 2025 and historically volatile cash flows. Technicals are a secondary drag because the stock is below major moving averages despite mixed momentum indicators. Valuation is moderate with a modest dividend yield, adding limited support.
Positive Factors
Revenue Growth Momentum
Sugi's sustained multi-year revenue expansion and the sharp 2025 acceleration indicate growing customer demand and market penetration in its drugstore and pharmacy segments. Persistent top-line growth supports scale benefits, reinvestment in stores/pharmacy services, and underpins medium-term cash generation and strategic initiatives.
Negative Factors
Rising Leverage
The material step-up in debt in 2025–2026 materially reduces financial headroom and raises interest and refinancing risk. With higher leverage, Sugi has less flexibility to pursue opportunistic investments or absorb revenue shocks, making medium-term strategic options and dividend/capital allocation more constrained.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth Momentum
Sugi's sustained multi-year revenue expansion and the sharp 2025 acceleration indicate growing customer demand and market penetration in its drugstore and pharmacy segments. Persistent top-line growth supports scale benefits, reinvestment in stores/pharmacy services, and underpins medium-term cash generation and strategic initiatives.
Read all positive factors
Sugi Holdings Co (7649) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥546.32B
Dividend Yield1.24%
Average Volume (3M)634.13K
Price to Earnings (P/E)16.7
Beta (1Y)0.20
Revenue Growth12.20%
EPS Growth-25.42%
CountryJP
Employees13,417
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)169.41
Shares Outstanding195,074,510
10 Day Avg. Volume884,930
30 Day Avg. Volume634,130
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)2.24
Price to Sales (P/S)0.64
P/FCF Ratio10.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥3,386.67Price Target Upside16.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)179.59
Revenue Forecast (FY)¥1.10T
Sugi Holdings Co Business Overview & Revenue Model
Company Description
Sugi Holdings Co.,Ltd. operates drugstores in Japan. The company also provides self-care support services, including meal delivery, cancer and other health checkups, specific health guidance, health information, and community comprehensive agreeme...
How the Company Makes Money
Sugi Holdings primarily earns revenue through (1) retail sales at its drugstores and (2) prescription dispensing services at in-store (or adjacent) pharmacies. Retail revenue is generated from the sale of over-the-counter pharmaceuticals, cosmetic...
Sugi Holdings Co Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
62
Positive
Cash Flow
74
Positive
| Breakdown | TTM | Feb 2026 | Feb 2026 | Feb 2025 | Feb 2024 | Feb 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.04T | 1.01T | 878.02B | 744.48B | 667.65B | 625.48B |
| Gross Profit | 328.93B | 321.20B | 275.04B | 228.84B | 202.52B | 191.49B |
| EBITDA | 66.73B | 66.16B | 56.18B | 46.24B | 40.56B | 38.74B |
| Net Income | 30.66B | 44.98B | 25.69B | 21.98B | 19.01B | 19.39B |
Balance Sheet | ||||||
| Total Assets | 638.46B | 614.49B | 495.12B | 391.99B | 353.25B | 336.38B |
| Cash, Cash Equivalents and Short-Term Investments | 124.63B | 111.21B | 52.79B | 47.43B | 70.64B | 71.83B |
| Total Debt | 92.88B | 94.04B | 47.72B | 2.76B | 1.95B | 2.31B |
| Total Liabilities | 344.53B | 324.02B | 244.41B | 158.62B | 136.71B | 122.49B |
| Stockholders Equity | 293.91B | 290.46B | 250.70B | 233.36B | 216.54B | 213.89B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 63.69B | 13.31B | 8.21B | 20.09B | -13.57B |
| Operating Cash Flow | 0.00 | 86.78B | 36.94B | 39.04B | 38.28B | 7.17B |
| Investing Cash Flow | 0.00 | -69.64B | -33.28B | -30.98B | -23.26B | -23.89B |
| Financing Cash Flow | 0.00 | 41.21B | 11.63B | -5.28B | -14.21B | -5.29B |
Sugi Holdings Co Technical Analysis
Negative
2910.00
Price Trends
2969.68
Negative
3138.51
Negative
3357.34
Negative
Market Momentum
-73.20
Positive
38.26
Neutral
12.59
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7649, the sentiment is Negative. The current price of 2910 is above the 20-day moving average (MA) of 2900.52, below the 50-day MA of 2969.68, and below the 200-day MA of 3357.34, indicating a bearish trend. The MACD of -73.20 indicates Positive momentum. The RSI at 38.26 is Neutral, neither overbought nor oversold. The STOCH value of 12.59 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7649.
Sugi Holdings Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ¥210.52B | 12.66 | ― | 2.35% | 8.76% | 8.19% | |
68 Neutral | ¥441.97B | 14.09 | 11.29% | 3.42% | 5.08% | 2.07% | |
67 Neutral | ¥546.32B | 16.66 | 10.75% | 1.20% | 12.20% | -25.42% | |
64 Neutral | ¥1.09T | 18.84 | 7.67% | 2.04% | ― | ― | |
64 Neutral | ¥508.09B | 15.79 | ― | 1.28% | 8.72% | 3.45% | |
54 Neutral | ¥384.37B | 22.68 | ― | 0.41% | 13.04% | 0.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:7649
Sugi Holdings Co
2,757.00
-1,088.21
-28.30%
JP:9989
Sundrug Co
3,688.00
-918.92
-19.95%
JP:3391
TSURUHA Holdings
2,389.00
160.58
7.21%
JP:3148
Create SD Holdings Co., Ltd.
3,265.00
-193.31
-5.59%
JP:3349
COSMOS Pharmaceutical Corporation
6,323.00
-3,465.42
-35.40%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
3,968.00
-166.27
-4.02%
Sugi Holdings Co Corporate Events
Sugi Holdings Grows Sales but Forecasts Profit Decline as It Plans Stock Split and New Subsidiary
Jul 9, 2026
Sugi Holdings reported a 10.1% year-on-year rise in net sales to ¥270.2 billion for the quarter ended May 31, 2026, with operating profit up 10.9% to ¥12.2 billion and EBITDA up 7.9%, while profit attributable to owners of the parent plu...
Sugi Holdings taps GIC in ¥16 billion share issue to fund healthcare growth
Jul 9, 2026
Sugi Holdings has approved a third-party allotment of 5,082,000 new shares to GIC Private Limited at ¥3,195 per share, raising about ¥16 billion net to strengthen its balance sheet. The move is intended to fund discontinuous growth, incl...
Sugi Holdings Completes Treasury Stock Disposition for Restricted Stock Compensation
Jun 15, 2026
Sugi Holdings has completed the payment procedures for a previously approved disposition of treasury stock to be used as restricted stock remuneration. The transaction involves issuing 34,219 shares of common stock at ¥2,991 per share, for a ...
Sugi Holdings Posts Strong May Sales and Expands Store Network
Jun 15, 2026
Sugi Holdings reported that in May 2026, existing-store sales at Sugi Pharmacy rose 6.4% year on year, driven by a 6.6% increase in the drugstore segment and a 5.8% gain in the prescription business. On an all-store basis, which reflects network e...
SUGI Holdings Clarifies Relationship With Major Associated Shareholder Sugi Shoji
May 28, 2026
SUGI Holdings has disclosed that Sugi Shoji Co., Ltd., an asset management company for President Katsunori Sugiura and Senior Vice President Shinya Sugiura, holds 37.43% of its voting rights, while the two executives directly hold an additional 0....
Sugi Holdings to Grant ¥102 Million in Restricted Stock to Group Executives
May 21, 2026
Sugi Holdings has approved the disposal of 34,219 shares of treasury stock, worth about ¥102 million, as restricted stock remuneration to 45 internal directors, executive officers, and group company directors. The move expands a stock-based c...
Sugi Holdings Posts Strong April Sales Growth and Expands Store Network
May 15, 2026
Sugi Holdings reported that in April 2026, Sugi Pharmacy’s existing-store sales rose 5.3% year on year, driven by a 3.6% increase in the drugstore business and a robust 9.3% gain in the prescription business. On an all-store basis, sales cli...
Sugi Holdings Posts Strong March Sales and Expands Store Network
Apr 15, 2026
Sugi Holdings reported that in March 2026 existing-store sales at Sugi Pharmacy rose 5.7% year on year, driven by a 3.2% increase in the drugstore segment and a robust 12.0% gain in the prescription business. On an all-store basis, sales climbed 8...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.